Epitope structure and binding affinity of single chain llama anti-β-amyloid antibodies revealed by proteolytic excision affinity-mass spectrometry

Journal of Molecular Recognition

Volumn 26, Issue 1, 2013, Pages 1-9

  Paraschiv, Gabriela ^a   Vincke, Cécile ^b,c   Czaplewska, Paulina ^d   Manea, Marilena ^a   Muyldermans, Serge ^b,c   Przybylski, Michael ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF GDA SK   (Poland)

Author keywords

amyloid (A ) peptide; A (17 28) epitope; affinity mass spectrometry; proteolytic excision; proteolytic extraction; single chain llama anti A antibody

Indexed keywords

AMYLOID BETA PROTEIN; EPITOPE; PEPTIDE HYDROLASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; ARTIODACTYLA; CHEMISTRY; IMMUNOLOGY; MASS SPECTROMETRY; METHODOLOGY; MOLECULAR GENETICS; PROTEIN DEGRADATION;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; CAMELIDS, NEW WORLD; EPITOPES; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PROTEOLYSIS; SINGLE-CHAIN ANTIBODIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

CAMELIDAE; LAMA (MAMMAL);

EID: 84871830803     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2210     Document Type: Article

References (50)

1. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH. 2005. Prototype Alzheimers disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174: 1580-1586.
2. Amit AG, Mariuzza RA, Phillips SE, Poljak RJ. 1986. Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science 233: 747-753.
3. Atassi MZ. 1975. Antigenic structure of myoglobin: the complete immunochemical anatomy of a protein and conclusions relating to antigenic structures of proteins. Immunochemistry 12: 423-438.
4. Benjamin DC, Berzofsky JA, East IJ, Gurd FR, Hannum C, Leach SJ, Margoliash E, Michael JG, Miller A, Prager EM, Reichlin M, Sercarz EE, Smith-Gill SJ, Todd PE, Wilson AC, 1984. The antigenic structure of proteins: a reappraisal. Annu. Rev. Immunol. 2: 67-101.
5. Check E. 2002. Nerve inflammation halts trial for Alzheimers drug. Nature 415: 462.
6. Dodel R, Bacher M, Przybylski M, Stefanescu R, Manea M. 2008. Diagnosis of Alzheimers disease and other neurodementing disorders. In European Patent Office. Vol. WO/2008/084402.
7. Dragusanu M, Petre BA, Slamnoiu S, Vlad C, Tu T, Przybylski M. 2010. On-line bioaffinity-electrospray mass spectrometry for simultaneous detection, identification, and quantification of protein-ligand interactions. J. Am. Soc. Mass Spectrom. 21: 1643-1648.
8. Esler WP, Wolfe MS. 2001. A portrait of Alzheimer secretases-new features and familiar faces. Science 293: 1449-1454.
9. Ewert S, Cambillau C, Conrath K, Pluckthun A. 2002. Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 41: 3628-3636.
10. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. 2004. Immunotherapy for Alzheimers disease. Proc. Natl. Acad. Sci. U.S.A. 101(Suppl 2): 14657-14662.
11. Glocker MO, Borchers C, Fiedler W, Suckau D, Przybylski M. 1994. Molecular characterization of surface topology in protein tertiary structures by amino-acylation and mass spectrometric peptide mapping. Bioconjug. Chem. 5: 583-590.
12. Grau S, Baldi A, Bussani R, Tian X, Stefanescu R, Przybylski M, Richards P, Jones SA, Shridhar V, Clausen T, Ehrmann M. 2005. Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc. Natl. Acad. Sci. U.S.A. 102: 6021-6026.
13. Gronewold TMA. 2007. Surface acoustic wave sensors in the bioanalytical field: recent trends and challenges. Anal. Chim. Acta 603: 119-128.
14. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R. 1993. Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
15. Juszczyk P, Paraschiv G, Szymanska A, Kolodziejczyk AS, Rodziewicz-Motowidlo S, Grzonka Z, Przybylski M. 2009. Binding epitopes and interaction structure of the neuroprotective protease inhibitor cystatin C with beta-amyloid revealed by proteolytic excision mass spectrometry and molecular docking simulation. J. Med. Chem. 52: 2420-2428.
16. Laver WG, Air GM, Webster RG, Smith-Gill SJ. 1990. Epitopes on protein antigens: misconceptions and realities. Cell 61: 553-556.
17. Lazo ND, Downing DT. 1997. Circular dichroism of model peptides emulating the amphipathic alpha-helical regions of intermediate filaments. Biochemistry 36: 2559-2565.
18. van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P, Verrips CT. 1999. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta 1431: 37-46.
19. Macht M, Fiedler W, Kurzinger K, Przybylski M. 1996. Mass spectrometric mapping of protein epitope structures of myocardial infarct markers myoglobin and troponin T. Biochemistry 35: 15633-15639.
20. Macht M, Marquardt A, Deininger SO, Damoc E, Kohlmann M, Przybylski M. 2004. "Affinity-proteomics": direct protein identification from biological material using mass spectrometric epitope mapping. Anal. Bioanal. Chem. 378: 1102-1111.
21. Malave A, Schlecht U, Gronewold TMA, Perpeet M, Tewes M. 2006. Lithium tantalate surface acoustic wave sensors for bio-analytical applications, In sensors 5th IEEE Conference on Daegu 604-607.
22. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P. 2002. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8: 1263-1269.
23. Merutka G, Lipton W, Shalongo W, Park SH, Stellwagen E. 1990. Effect of central-residue replacements on the helical stability of a monomeric peptide. Biochemistry 29: 7511-7515.
24. Millar AL, Jackson NA, Dalton H, Jennings KR, Levi M, Wahren B, Dimmock NJ. 1998. Rapid analysis of epitope-paratope interactions between HIV-1 and a 17-amino-acid neutralizing microantibody by electrospray ionization mass spectrometry. Eur. J. Biochem. 258: 164-169.
25. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J. 2000. Substitutions at codon 22 of Alzheimers abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J. Biol. Chem. 275: 27110-27116.
26. Moise A, Andre S, Eggers F, Krzeminski M, Przybylski M, Gabius HJ. 2011. Toward bioinspired galectin mimetics: identification of ligandcontacting peptides by proteolytic-excision mass spectrometry. J. Am. Chem. Soc. 133: 14844-14847.
27. Muyldermans S. 2001. Single domain camel antibodies: current status. J. Biotechnol. 74: 277-302.
28. Muyldermans S, Lauwereys M. 1999. Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies. J. Mol. Recognit. 12: 131-140.
29. Muyldermans S, Cambillau C, Wyns L. 2001. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem. Sci. 26: 230-235.
30. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9: 448-452.
31. Papac DI, Hoyes J, Tomer KB. 1994. Epitope mapping of the gastrinreleasing peptide/anti-bombesin monoclonal antibody complex by proteolysis followed by matrix-assisted laser desorption ionization mass spectrometry. Protein Sci. 3: 1485-1492.
32. Parker CE, Papac DI, Trojak SK, Tomer KB. 1996. Epitope mapping by mass spectrometry: determination of an epitope on HIV-1 IIIB p26 recognized by a monoclonal antibody. J. Immunol. 157: 198-206.
33. Perpeet M, Glass S, Gronewold T, Kiwitz A, Malavé A, Stoyanov I, Tewes M, Quandt E. 2006. SAW sensor system for marker-free molecular interaction analysis. LANL 39: 1747-1757.
34. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. 2002. A structural model for Alzheimers beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U.S.A. 99: 16742-16747.
35. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. 1995. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64: 253-265.
36. Przybylski M, Stefanescu R, Manea M, Perdivara I, Cozma C, Moise A, Paraschiv G, Juszczyk P, Marquardt A. 2007. New molecular approaches for immunotherapy and diagnosis of Alzheimers disease based on epitope-specific serum beta-amyloid antibodies. In 7th Austral. Pept. Symposium, Cairns. abstr. p. 32.
37. van Regenmortel MH. 1988. Which value of antigenic valency should be used in antibody avidity calculations with multivalent antigens? Mol. Immunol. 25: 565-567.
38. Schultz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, Pavlovic J, Wollmer MA, Nitsch RM, Moelling K. 2004. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimers disease. J. Mol. Med. 82: 706-714.
39. Selkoe DJ. 1991. Amyloid protein and Alzheimers disease. Sci. Am. 265: 68-71, 74-66, 78.
40. Selkoe DJ. 1994. Alzheimers disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53: 438-447.
41. Serpell LC, Blake CC, Fraser PE. 2000. Molecular structure of a fibrillar Alzheimers A beta fragment. Biochemistry 39: 13269-13275.
42. Small DH, Mok SS, Bornstein JC. 2001. Alzheimers disease and abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2: 595-598.
43. Stefanescu R, Iacob RE, Damoc EN, Marquardt A, Amstalden E, Manea M, Perdivara I, Maftei M, Paraschiv G, Przybylski M. 2007. Mass spectrometric approaches for elucidation of antigenantibody recognition structures in molecular immunology. Eur. J. Mass Spectrom. (Chichester, Eng.) 13: 69-75.
44. Suckau D, Kohl J, Karwath G, Schneider K, Casaretto M, Bitter-Suermann D, Przybylski M. 1990.Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping. Proc. Natl. Acad. Sci. U.S.A. 87: 9848-9852.
45. Tycko R. 2003. Insights into the amyloid folding problem from solid-state NMR. Biochemistry 42: 3151-3159.
46. Van Regenmortel MHV. 1996. Mapping epitope structure and activity: from one-dimensional prediction to four-dimensional description of antigenic specificity. Methods 9: 465-472.
47. Vincke C. 2009. Humanization of nanobodies and identification of nanobodies for Alzheimers disease immunotherapy. Dissertation Vrije Universiteit Brussels.
48. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341: 544-546.
49. Yu L, Gaskell SJ, Brookman JL. 1998. Epitope mapping of monoclonal antibodies by mass spectrometry: identification of protein antigens in complex biological systems. J. Am. Soc. Mass Spectrom. 9: 208-215.
50. Zhao Y, Chalt BT. 1994. Protein epitope mapping by mass spectrometry. Anal. Chem. 66: 3723-3726.